Clinical trials: Anti-Retroviral Agents
Malnutrition, HIV/AIDS
Nutritional Rehabilitation in Senegalese HIV-infected Children and Adolescents
Severe (SAM, Body Mass Index-z < -3) and moderate (MAM, -3 ≤ BMI-z < -2) acute malnutrition, highly prevalent in HIV-infected children and adolescents, is an independent risk factor of death, even when antiretroviral treatment…
- Trial name
- SNAC'S (NCT03101852)
- Testing
- Plumpy Nut, Plumpy Sup
- Volunteers
- 185 people
- Sponsor
- Institut de Recherche pour le Developpement
HIV Infections
Raltegravir + Lopinavir/Ritonavir or Emtricitabine/Tenofovir for HIV Treatment Naive Subjects
A prospective, randomized, open-label pilot study to assess virologic suppression and immunologic recovery associated with a two-drug antiretroviral regimen of Raltegravir and the protease inhibitor lopinavir/ritonavir (LPV/r)…
- Trial name
- HIV (NCT00654147)
- Testing
- Raltegravir & Lopinavir/ritonavir, Raltegravir and emtricitabine/tenofovir
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Margaret A. Fischl, M.D.
HIV Infections, Pneumococcal Infections
Safety of and Immune Response to a Pneumococcal Vaccine (PncCV) in HIV Infected and Uninfected Children
Infection by Streptococcal pneumoniae is a common invasive bacterial infection in HIV infected children. The purpose of this study is to determine the safety of and immune response to a pneumococcal polysaccharide-protein…
- Trial name
- NCT00099658
- Testing
- Pneumococcal polysaccharide-protein conjugate vaccine
- Volunteers
- 579 people, healthy volunteers welcome
- Sponsor
- CIPRA SA
HIV Infections
VERxVE Study on Efficacy and Safety of Nevirapine XR in Comparison to Nevirapine IR With Truvada in Naive HIV+ Patients
The primary objective of this study is to evaluate the efficacy of 400 mg QD nevirapine extended release (NVP XR) formulation versus 200 mg BID nevirapine immediate release (NVP IR) in ARV therapy naïve HIV-1 infected patients…
- Trial name
- NCT00561925
- Testing
- nevirapine IR, nevirapine XR
- Where
- 202 sites in United States, Argentina and 19 more
- Volunteers
- 1,068 people
- Sponsor
- Boehringer Ingelheim
Human Immunodeficiency Virus, Facial Lipoatrophy
Safety, Efficacy and Psychological Effects of Treating Antiretroviral Drug-Induced Facial Lipoatrophy With Bio-Alcamid
Evaluate and record any changes in the Quality of Life and psychological state of the affected study group following treatment with Bio-Alcamid.
- Trial name
- NCT00333684
- Testing
- BIO-ALCAMID SOFT TISSUE ENDOPROSTHESIS
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Canadian Immunodeficiency Research Collaborative
HIV-1, HIV Infections
Effect Of An Integrase Inhibitor On The Latency And Reservoir Of HIV-1
The presence of a pool of cells latently infected by HIV-1 in patients taking HAART and with a viral load below 50 copies/mL is the main limitation to eradication of the virus from the body.
- Trial name
- NCT00807443
- Testing
- Raltegravir
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
HIV Infections
China Antiretroviral Treatment Adherence for Life
This study focuses on collecting and analyzing quantitative data related to adherence to antiretroviral treatment from patients in Dali, China, over a one-year time-frame and generating preliminary data on an intervention…
- Trial name
- AFL (NCT00661258)
- Testing
- Electronic drug monitoring feedback data
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Boston University
Human Immunodeficiency Virus Infection (HIV)
Innate-like and NK Signatures in Chronic-Treated HIV Infection INSTINCT-HIV
Infection with the human immunodeficiency virus (HIV) is a chronic condition requiring lifelong antiretroviral therapy (ART). Despite prolonged virological control under suppressive ART, HIV persists in the form of a stable viral…
- Trial name
- INSTINCT-HIV (NCT07849933)
- Testing
- Blood test
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
HIV Infections
A Comparison of Epivir Plus Crixivan Combined With Zerit or Retrovir in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
To evaluate the tolerance, and comparative virologic and immunologic effects of the two combination regimens.
- Trial name
- NCT00002369
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Pilot Study of LTB4 in HIV-1 Infected Adults
This is a pilot study to assess the safety and antiretroviral activity of a naturally occuring substance known as Leukotriene B4(LTB4).
- Trial name
- NCT00251537
- Testing
- LTB4
- Where
- 7 sites in Canada
- Volunteers
- 40 people
- Sponsor
- LTB4 Sweden AB
HIV Infections
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
The trial is an open-label, multicenter, prospective, randomized trial in 2 parallel groups, evaluating at W48, the non-inferiority of antiretroviral treatment taken 4 consecutive days a week versus continuous therapy, in HIV…
- Trial name
- QUATUOR (NCT03256422)
- Testing
- Treatment discontinuation
- Where
- 63 sites in France
- Volunteers
- 640 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hiv
Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART
To evaluate the effect of early viral reactivation by latency reversing agents (LRA) and/or administration of potent broadly neutralizing antibodies (bNAb) on the size of the latent HIV-1 reservoir in treatment naïve HIV-1…
- Trial name
- eCLEAR (NCT03041012)
- Testing
- Romidepsin, 3BNC117, Antiretrovirals
- Where
- 7 sites in Denmark, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Aarhus University Hospital
HIV Infections
Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)
This study will test the safety and immunogenicity of the gp120/NefTat/AS02A vaccine candidate in individuals with chronic HIV-1 infection successfully treated with HAART.
- Trial name
- NCT00117429
- Testing
- HIV gp120/NefTat/AS02A Vaccine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Marcus Altfeld, M.D., Ph.D.
HIV Infections
Safety and Effectiveness of Giving Two Nucleoside Reverse Transcriptase Inhibitors Alone or in Combination With 141W94 to HIV-Infected Children Who Have Never Received Protease Inhibitors
The purpose of this study is to see if it is safe and effective to add a new protease inhibitor (PI), 141W94, to an anti-HIV regimen that includes 2 nucleoside reverse transcriptase inhibitors (NRTIs).
- Trial name
- NCT00002193
- Testing
- Amprenavir
- Where
- 2 sites in United States
- Volunteers
- 210 people
- Sponsor
- Glaxo Wellcome
Hepatitis C, Chronic, HIV Infection
Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection
The main objective is to evaluate the hepatic safety of raltegravir when compared to efavirenz, both in combination with tenofovir and emtricitabine as first-line HIV treatment in patients with HIV and hepatitis C coinfection.
- Trial name
- NCT01147107
- Testing
- Raltegravir, Efavirenz
- Where
- 2 sites in Vietnam
- Volunteers
- 80 people
- Sponsor
- University of Hawaii
Cryptococcal Antigenemia, HIV-1-infection
Optimizing Care for Cryptococcal Antigenemia: Evaluation of Short Course Fluconazole and ART Timing Among CrAg+ Persons With Low Titers
This randomized clinical trial will evaluate the optimal duration of fluconazole therapy and timing of antiretroviral therapy initiation among HIV-infected persons with asymptomatic cryptococcal antigenemia and low cryptococcal…
- Conditions
- Cryptococcal Antigenemia, HIV-1-infection, Cryptococcal Infection, Cryptococcal Meningitis
- Trial name
- NCT07743593
- Testing
- Immediate ART Initiation, Delayed ART Initiation, 10-Week Fluconazole
- Where
- Uganda
- Volunteers
- 505 people
- Sponsor
- University of Minnesota
HIV Infection
Immune and Viral Status of HIV-Infected Patients After Stopping Combination Antiretroviral Therapy
This study will examine the effects of increases in HIV blood levels on the immune system. A better understanding of how HIV alters the immune response may lead to development of effective immune-based therapies against the…
- Trial name
- NCT00001899
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Evaluation of the Population-level Impact of PMTCT Option B+ in Zimbabwe
This study evaluates the impact of Zimbabwe's program for the prevention of mother-to-child HIV transmission (PMTCT) on vertical transmission of HIV infection and HIV-free survival among infants exposed to HIV.
- Trial name
- NCT03388398
- Volunteers
- 30,642 people
- Sponsor
- University of California, Berkeley
HIV Infections
Clinical Trial of CNS-targeted HAART (CIT2)
CIT2 is a strategy for targeting HAART (Highly Active Antiretroviral Therapy) to the CNS (Central Nervous System) in patients with HIV associated neurocognitive impairment (HNCI).
- Trial name
- NCT00624195
- Testing
- FDA Approved Antiretroviral Therapy (see list below)
- Where
- 5 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of California, San Diego
HIV Infections
Electronic Capture of Adherence Barriers for HIV Care
Adherence to antiretroviral therapy (ART) remains problematic. Our team has thus developed a new patient-reported measure of barriers to ART adherence (the I-Score) which will be completed by HIV patients through the Opal patient…
- Trial name
- CTNPT039 (NCT04702412)
- Testing
- The Opal patient portal and smartphone application combined with the I-Score patient-reported outcome measure
- Where
- Canada
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.